J&J has hypothesized that subcutaneous absorption of the drug may potentially enhance immune-mediated anticancer activity.

The deal with the U.K.’s Nuclear Decommissioning Authority runs for 15 years with an option to renew for a “potentially ...

After a long run of regulatory stumbles and the recent wit | "Following the withdrawal of Ocaliva from the U.S. market, we ...

Within the mammoth defense bill, the Biosecure Act has the potential to raise new hurdles for certain life sciences companies ...

As Eli Lilly gears up to support its partnered athletes, Team USA and the Games themselves at the Milano Cortina 2026 Olympic ...

With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship ...

As it kicks off a pivotal phase 3 trial of its investigational treatment for Angelman syndrome (AS), Ionis Pharmaceuticals is ...

With a fresh endorsement from the FDA, the last of five major drug approvals has fallen into place for GSK in 2025. | On ...

The combination of Keytruda and Padcev is taking another major step toward securing its position as a leading therapy in the ...

The Swedish drugmaker has come up short in its effort to push imlifidase into treatment of the autoimmune condition ...

Novo Nordisk, which has stumbled through a bit of a manufacturing hangover at a former Catalent production site it ...

In a Q&A for Fierce Pharma Marketing’s “Rising Stars” series, Andrew Willett discussed the path that led him to Lundbeck and ...